MYOS Co. (NASDAQ:MYOS) Director Christopher Pechock acquired 34,247 shares of the stock in a transaction dated Wednesday, March 27th. The shares were bought at an average price of $1.46 per share, with a total value of $50,000.62. Following the completion of the transaction, the director now directly owns 257,157 shares of the company’s stock, valued at $375,449.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of MYOS remained flat at $$1.40 during mid-day trading on Friday. The stock had a trading volume of 5,613 shares, compared to its average volume of 34,792. MYOS Co. has a 52 week low of $1.04 and a 52 week high of $2.50. The company has a market capitalization of $12.83 million, a P/E ratio of -3.11 and a beta of 0.64.
Separately, ValuEngine downgraded MYOS from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th.
WARNING: This piece of content was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/04/21/insider-buying-myos-co-myos-director-buys-50000-62-in-stock.html.
MYOS RENS Technology Inc, a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
Recommended Story: What is a blue-chip stock?
Receive News & Ratings for MYOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS and related companies with MarketBeat.com's FREE daily email newsletter.